FT Options’s Celldex Therapeutics CLDX Stock Holding History

FT Options’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-333	Closed	-$2K	–	388
2016 Q2	$2K	Buy	+333	New	+$21.1K	﹤0.01%	321

Other funds holding CLDX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FT Options's CLDX Position: Q3 2016 in Review

FT Options sold out of Celldex Therapeutics (CLDX) in Q3 2016, closing a stake of 87 shares — an estimated $5.42K sold.

FT Options first reported a position in CLDX in Q2 2016 and held it in 1 quarter. The position peaked at $6K in Q2 2016. 138 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

FT Options reported no remaining Celldex Therapeutics position as of Q3 2016 after selling out during the quarter.
FT Options sold 87 Celldex Therapeutics shares in Q3 2016, an estimated $5.42K.
FT Options first reported a position in Celldex Therapeutics in Q2 2016 and held it in 1 quarter.
FT Options's Celldex Therapeutics position peaked at $6K in Q2 2016.
138 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.